Sex-Specific Outcomes of Left Atrial Appendage Closure Versus Medical Therapy: The CLOSURE-AF-DZHK-16 Trial

31 August 2026 (13:30 - 13:45)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Professor Ingo Eitel

University Heart Center, Luebeck (Germany)

3 More presentations in this session

Presentation thumbnail

Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial

Professor J. Weizhu (Nanjing, CN)

Presentation thumbnail

Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian

Professor M. Sharma (Hamilton, CA)

Presentation thumbnail

Left Atrial Appendage Closure as an Alternative to NOAC for Stroke Prevention in Patients with Atrial Fibrillation at Low Bleeding Risk: A Patient-Level Meta-Analysis

Doctor M. Coylewright (Duluth, US)

Access the full session

Session thumbnail

Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure

The Event

Event poster

ESC Congress 2026

31 August 2026 13:30 CET

You may be interested in

Congress Presentation

Sex disparities in outcomes of left atrial appendage occlusion

28 August 2023

Congress Presentation

Left atrial appendage closure: integrating opposing trials

31 August 2026

Congress Presentation

Sex differences in the risk continuum of atrial fibrillation and stroke

28 August 2026

Congress Presentation

Sex differences in infarct–related cardiogenic shock: a secondary analysis of the ECLS–SHOCK trial

30 August 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources